Biote Corp. - Class A common stock (BTMD)

Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026.

Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company’s Board of Directors. In addition, Marc Beer, Biote’s Chairman, will assume the role of Executive Chairman.

Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the first quarter ended March 31, 2026.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the fourth quarter and full year ended December 31, 2025.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients’ lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the third quarter ended September 30, 2025.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2025.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

biote Corp.(NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2025.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that several members of its Board of Directors, along with CEO Bret Christensen, have made open market purchases of Biote’s common stock, acquiring an aggregate of approximately 260,000 shares.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 12, 2025, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company’s Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company’s Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executive Officer and Director, effective February 1, 2025.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Thursday, August 8, 2024, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz, stockholder of Biote, to resolve litigation (“Donovitz Litigation”). For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class A Shares, as applicable, owned by Ms. Donovitz and will release and cancel all of the approximately 4.0 million Paired Interests subject to contractual earnout provisions (“earnout shares”) owned by Ms. Donovitz for no additional monetary consideration. Biote intends to fund the repurchases in accordance with its existing capital allocation strategy.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024.

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement (the “Settlement Agreement”) that concludes outstanding litigation with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote.

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.